TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: Given that the overwhelming majority of chronic phase CML patients do not present with, or acquire TP53 mutations and have WT p5348,49, p53 activation represents a clinically tractable therapeutic strategy to achieve TFR, with a phase I/2 trial evaluating this strategy currently recruiting (NCT04835584).